Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY)

BACKGROUND: Secukinumab demonstrated superior efficacy over ustekinumab in the treatment of moderate to severe plaque psoriasis over 16 weeks in the CLARITY study and over 52 weeks in the CLEAR study. OBJECTIVE: To compare the efficacy and safety of secukinumab vs. ustekinumab over 52 weeks in CLARI...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagel, J., Blauvelt, A., Nia, J., Hashim, P., Patekar, M., de Vera, A., Ahmad, K., Paguet, B., Xia, S., Muscianisi, E., Lebwohl, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818402/
https://www.ncbi.nlm.nih.gov/pubmed/32365251
http://dx.doi.org/10.1111/jdv.16558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818402/
https://www.ncbi.nlm.nih.gov/pubmed/32365251
http://dx.doi.org/10.1111/jdv.16558

Ejemplares similares